Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction

Biomedicine and Pharmacotherapy

Volumn 64, Issue 10, 2010, Pages 663-671

  Konjevic G ^a,b   Mirjacic Martinovic K ^a   Vuletic A ^a   Radenkovic S ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cytokines; NK cell receptors; NK cells

Indexed keywords

ALPHA INTERFERON; CD16 ANTIGEN; CD161 ANTIGEN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; NATURAL KILLER CELL RECEPTOR NKG2D; STAT1 PROTEIN; STAT5 PROTEIN;

ADULT; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WESTERN BLOTTING;

ADULT; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTES; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, KIR2DL1; RECEPTORS, KIR2DL3; RECEPTORS, NATURAL KILLER CELL; UP-REGULATION;

EID: 78649880476     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.06.013     Document Type: Article

References (71)

1. Kiessling R., Klein E., Wigzell H. Natural killer cells in the mouse. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype I. Eur J Immunol 1975, 5:112-117.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
3. Robertson M.J., Ritz J. Biology and relevance of human natural killer cells. Blood 1990, 76:2421-2438.
4. Konjevic G., Schlesinger B., Cheng L., Olsen K.J., Podack E.R., Spuzic I. Analysis of perforin expression in human peripheral blood lymphocytes. CD56+ natural killer cell subsets and its induction by interleukin-2. Immunol Invest 1995, 24:499-507.
5. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
6. Strowig T., Brilot F., Münz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008, 180:7785-7791.
7. Nagler A., Lanier L.L., Cwirla S. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989, 143:3183-3191.
8. Lanier L.L., Le A.M., Civin C.I., Loken M.R., Phillips J.H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986, 136:4480-4486.
9. Warren H.S., Kinnear B.F. Quantitative analysis of the effect of CD16 ligation on human NK cell proliferation. J Immunol 1999, 162:735-742.
10. Mandelboim O., Malik P., Davis D.M., Jo C.H., Boyson J.E., Strominger J.L. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 1999, 96:5640-5644.
11. Lanier L.L. Natural killer cell receptor signaling. Curr Opin Immunol 2003, 15:308-314.
12. Farag S.S., Caligiuri M.A. Human natural killer cell development and biology. Blood Rev 2006, 20:123-137.
13. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790.
14. Van Belle T.L., von Herrath M.G. The role of the activating receptor NKG2D in autoimmunity. Mol Immunol 2009, 47:8-11.
15. Zhang Y., Zhao A., Wang X., Shi G., Jin H., Lin Q. Expressions of natural cytotoxicity receptors and NKG2D on decidual natural killer cells in patients having spontaneous abortions. Fertil Steril 2008, 90:1931-1937.
16. Diefenbach A., Hsia J.K., Hsiung M.Y., Raulet D.H. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003, 33:381-391.
17. Casado J.G., Pawelec G., Morgado S., Sanchez-Correa B., Delgado E., Gayoso I., et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 2009, 58:1517-1526.
18. Azzoni L., Zatsepina O., Abebe B., Bennett I.M., Kanakaraj P., Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 1998, 161:3493-3500.
19. Di Santo J.P. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006, 24:257-286.
20. Aldemir H., Prod'homme V., Dumaurier M.J., Retiere C., Poupon G., Cazareth J. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 2005, 175:7791-7795.
21. Rosen D.B., Bettadapura J., Alsharifi M., Mathew P.A., Warren H.S., Lanier L.L. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 2005, 175:7796-7799.
22. Uhrberg M., Valiante N.M., Shum B.P., Shilling H.G., Lienert-Weidenbach K., Corliss B., et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997, 7:753-763.
23. Trowsdale J., Parham P. Mini-review: defense strategies and immunity-related genes. Eur J Immunol 2004, 34:7-17.
24. Yawata M., Yawata N., Draghi M., Little A.M., Partheniou F., Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006, 203:633-645.
25. Naumova E., Mihaylova A., Ivanova M., Mihailova S. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol Immunother 2007, 56:95-100.
26. Kulkarni S., Martin M.P., Carrington M., The Yin Yang of HLA and KIR in human disease. Semin Immunol 2008, 20:343-352.
27. Ntrivalas E.I., Bowser C.R., Kwak-Kim J., Beaman K.D., Gilman-Sachs A. Expression of killer immunoglobulin-like receptors on peripheral blood NK cell subsets of women with recurrent spontaneous abortions or implantation failures. Am J Reprod Immunol 2005, 53:215-221.
28. Swann J.B., Hayakawa Y., Zerafa N., Sheehan K.C., Scott B., Schreiber R.D., et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007, 178:7540-7549.
29. Konjević G., Jović V., Vuletić A., Radulović S., Jelić S., Spuzić I. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest 2007, 37:887-896.
30. Bremers A.J., Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000, 34:1-25.
31. Darnell J.E. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 1998, 18:549-554.
32. Lee C.K., Rao D.T., Gertner R., Gimeno R., Frey A.B., Levy D.E. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000, 165:3571-3577.
33. Darnell J.E., Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
34. Au W.C., Moore P.A., Lowther W., Juang Y.T., Pitha P.M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci U S A 1995, 92:11657-11661.
35. Frank D.A., Robertson M.J., Bonni A., Ritz J., Greenberg M.E. Proc Natl Acad Sci U S A. Interleukin 2 signaling involves the phosphorylation of Stat proteins 1995, 17:7779-7783.
36. Tarner I.H., Müller-Ladner U., Gay S. Emerging targets of biologic therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2007, 3:336-345.
37. Kovarik J., Boudny V., Kocak I., Lauerova L., Fait V., Vagundova M. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 2003, 12:335-340.
38. Varker K.A., Kondadasula S.V., Go M.R., Lesinski G.B., Ghosh-Berkebile R., Lehman A., et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res 2006, 12:5850-5858.
39. Critchley-Thorne R.J., Yan N., Nacu S., Weber J., Holmes S.P., Lee P.P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:176.
40. Caligiuri M.A., Zmuidzinas A., Manley T.J., Levine H., Smith K.A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high-affinity receptors. J Exp Med 1990, 171:1509-1526.
41. Chan A., Hong D.L., Atzberger A., Kollnberger S., Filer A.D., Buckley C.D., et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007, 179:89-94.
42. Romagnani C., Juelke K., Falco M., Morandi B., D'Agostino A., Costa R., et al. CD56brightCD16- killer Ig-like receptor_NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 2007, 178:4947-4955.
43. Lima M., Teixeira M.A., Queirós M.L., Leite M., Santos A.H., Justiça B., et al. Immunophenotypic characterization of normal blood CD56+lo versus CD56+hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties. Blood Cells Mol Dis 2001, 27:731-743.
44. Takahashi E., Kuranaga N., Satoh K., Habu Y., Shinomiya N., Asano T., et al. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scand J Immunol 2007, 65:126-138.
45. Konjević G., Martinović Martinovic K., Jurisić V., Babović N., Spuzić I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 2009, 14:258-270.
46. Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedmah H, Fahey J, editors. Manual of clinical laboratory immunology. Washington DC: American Society for Microbiology; 1986. p. 226-35.
47. Brown R.L., Ortaldo J.R., Griffith R.L., Blanca I., Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 1985, 81:207-214.
48. Clausen J., Kircher B., Auberger J., Schumacher P., Ulmer H., Hetzenauer G., et al. The role of missing killer-cell Ig-like receptor (KIR) ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Biol Blood Marrow Transplant 2010, 16:273-280.
49. Rezaei A., Dabbagh A. T-helper (1) cytokines increase during early pregnancy in women with a history of recurrent spontaneous abortion. Med Sci Monit 2002, 8:CR607-CR610.
50. Smyth M.J., Cretney E., Kelly J.M., Westwood J.A., Street S.E., Yagita H., et al. Activation of NK cell cytotoxicity. Mol Immunol 2005, 42:501-510.
51. Zhang C., Zhang J., Sun R., Feng J., Wei H., Tian Z. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int Immunopharmacol 2005, 5:1057-1067.
52. Sutherland C.L., Chalupny N.J., Schooley K., VandenBos T., Kubin M., Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002, 168:671-679.
53. Castriconi R., Cantoni C., Della Chiesa M., Vitale M., Marcenaro E., Conte R., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003, 100:4120-4125.
54. Epling-Burnette P.K., Bai F., Painter J.S., Rollison D.E., Salih H.R., Krusch M., et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007, 109:4816-4824.
55. Smyth M.J., Swann J., Kelly J.M., Cretney E., Yokoyama W.M., Diefenbach A., et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 2004, 10:1325-1335.
56. Lu C.C., Chen J.K. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways. J Cell Physiol 2010, 223:343-345.
57. Poggi A., Costa P., Tomasello E., Moretta L. IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation. Eur J Immunol 1998, 28:1611-1616.
58. Kogure T., Fujinaga H., Niizawa A., Hai L.X., Shimada Y., Ochiai H., et al. Killer-cell inhibitory receptors. CD158a/b, are unregulated by interleukin-2, but not interferon-gamma or interleukin-4. Mediators Inflamm 1999, 8:313-318.
59. Shin E.C., Choi K.S., Kim S.J., Shin J.S. Modulation of the surface expression of CD158 killer cell Ig-like receptor by interleukin-2 and transforming growth factor-beta. Yonsei Med J 2004, 45:510-514.
60. Varker K.A., Terrell C.E., Welt M., Suleiman S., Thornton L., Andersen B.L., et al. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res 2007, 139:36-44.
61. Kogure T., Niizawa A., Hai L.X., Fujinaga H., Shimada Y., Ochiai H., et al. Effect of interleukin 2 on killer cell inhibitory receptors in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:166-169.
62. Reiter Z. Interferon-a major regulator of natural killer cell-mediated cytotoxicity. J Interferon Res 1993, 13:247-257.
63. Lesinski G.B., Valentino D., Hade E.M., Jones S., Magro C., Chaudhury A.R., et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 2005, 54:815-825.
64. Lesinski G.B., Trefry J., Brasdovich M., Kondadasula S.V., Sackey K., Zimmerer J.M., et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 2007, 13:5010-5019.
65. Zimmerer J.M., Lesinski G.B., Ruppert A.S., Radmacher M.D., Noble C., Kendra K., et al. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res 2008, 14:5900-5906.
66. Liang S., Wei H., Sun R., Tian Z. IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 2003, 23:190-199.
67. Critchley-Thorne R.J., Simons D.L., Yan N., Miyahira A.K., Dirbas F.M., Johnson D.L., et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A 2009, 106:9010-9015.
68. Kröger A., Köster M., Schroeder K., Hauser H., Mueller P.P. Activities of IRF-1. J Interferon Cytokine Res 2002, 22:5-14.
69. Lehtonen A., Lund R., Lahesmaa R., Julkunen I., Sareneva T., Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 2003, 24:81-90.
70. Ferlazzo G., Münz C. Dendritic cell interactions with NK cells from different tissues. J Clin Immunol 2009, 29:265-273.
71. Konjević G., Mirjačić Martinović K., Vuletić A., Jurisić V., Spužić I. Distribution of several activating and inhibitory receptors on CD3(-)CD16(+) NK cells and their correlation with NK cell function in healthy individuals. J Membr Biol 2009, 230:113-123.